Business Development
What can we do for you?
R&D-Biopharmaceuticals offers the products platform as a partnering strategy to develop drug conjugates against validated molecular targets. Those drug conjugates are well suited to complement / replace conventional chemotherapeutics and therefore, represent a drug engine generating substantial product opportunities in areas of high unmet medical need.
R&D News
Tubulysins / Cytolysins
The recently discovered natural product class of the tubulysins show a very high cytotoxic activity against in vitro and in vivo tumour models, especially against resistant tumour cell lines. >> more
Epothilones
The FDA approved the first epothilone drug (IXEMPRA™) for BMS in October 2007. Further drug candidates of this natural products class are currently investigated in several clinical trials by several companies. >> more
R&D GmbH, Am Klopferspitz 19, D-82152 Planegg-Martinsried © 2010